IGF1R and neoplasm: Recently, a clinical study demonstrated a correlation between IGF-1R signaling and tumor aggressiveness in PDAC patients [15], and increased exposure to ganitumab was found to be associated with improved overall survival and progression free survival in metastatic PDAC [30].